九洲藥業(603456.SH):擬出資5000萬元投設浙江瑞博生命科學技術
格隆匯 8 月 25日丨九洲藥業(603456.SH)公佈,公司基於公司不斷拓展現有全球CDMO業務範圍,構建一體化醫藥服務生態圈,確保CDMO業務未來的可持續高效發展的目的,於2020年8月25日召開第六屆第二十七次董事會,會議審議通過了《關於擬設立全資子公司的議案》,擬以自有資金出資人民幣5000萬元投資設立全資子公司浙江瑞博生命科學技術有限公司(暫定名,以工商註冊登記為準)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.